FEATURED ARTICLES
Designing Trials Patients Can Actually Complete: Lessons From The SWIFT Deep TMS Study
Being time conscious and attuned to patient needs are two contributing factors to trials that recruit and retain patients for the duration.
-
5 Critical Risks With The FDA's Real-Time Trial Monitoring
Life science legal experts Kimberly Chew and Odette Hauke cover the FDA proof-of-concept real-time clinical trials (RTCTs) and expose five major issues that must be addressed before the pilot expands.
-
Precision Medicine Needs Better Infrastructure — And We Already Have The Models For It
Standard methods for evaluating clinical trial representativeness perform poorly when the trial population differs from the broader disease population in a patient registry. June Cha, Ph.D., MPH, explains how the right metrics can make a difference.
-
A Biomarker Playbook For Building Faster, Smarter Clinical Trials
Not every trial needs a biomarker, but every development leader should be assessing whether they can be effectively used to improve trial design, boost enrollment, reduce operational waste, and increase the likelihood that a study will answer the question it was built to answer.